NextCure (NASDAQ: NXTC) director receives stock options grant for 3,510 shares

Rhea-AI Filing Summary

NextCure, Inc. director David S. Kabakoff received a stock option grant giving him the right to buy 3,510 shares of common stock at an exercise price of $2.02 per share as compensation. Following this award, he holds stock options for 3,510 shares directly.

The option vests in full on the earlier of June 18, 2027 or the date of NextCure’s 2027 annual stockholders’ meeting, meaning it becomes exercisable at that time. The option expires on June 17, 2036, providing a long-dated incentive tied to the company’s future performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider KABAKOFF DAVID S

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	3,510	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 3,510 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 3,510 shares Exercise price: $2.02 per share Post-grant options held: 3,510 shares +2 more

5 metrics

Option grant size 3,510 shares Stock options underlying common stock granted to director

Exercise price $2.02 per share Conversion or exercise price of stock option

Post-grant options held 3,510 shares Total stock options following the transaction

Vesting date June 18, 2027 Vests on earlier of this date or 2027 annual meeting

Expiration date June 17, 2036 Option expiration for the stock option grant

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, Grant, award, or other acquisition, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 2.0200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-17T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vests in full financial

"The option vests in full on the earlier of June 18, 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KABAKOFF DAVID S

(Last) (First) (Middle)

C/O NEXTCURE, INC.

9000 VIRGINIA MANOR ROAD, SUITE 200

(Street)

BELTSVILLE MARYLAND 20705

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.02	06/18/2026		A		3,510		(1)	06/17/2036	Common Stock	3,510	$0	3,510	D

Explanation of Responses:

1. The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

	/s/ Steven P. Cobourn, as attorney-in-fact for David S. Kabakoff	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did NextCure (NXTC) report for David S. Kabakoff?

NextCure reported that director David S. Kabakoff received a grant of stock options for 3,510 shares of common stock at an exercise price of $2.02 per share. This is a compensation-related award, not an open-market stock purchase or sale.

What are the terms of David S. Kabakoff’s new NextCure (NXTC) stock options?

Kabakoff’s stock option covers 3,510 underlying common shares with an exercise price of $2.02 per share and expires on June 17, 2036. The long expiration gives him many years to decide whether to exercise if conditions become favorable.

When do the newly granted NextCure (NXTC) stock options to David S. Kabakoff vest?

The options vest in full on the earlier of June 18, 2027 or the date of NextCure’s 2027 annual meeting of stockholders. Once vested, Kabakoff can choose to exercise at the fixed $2.02 per-share price before expiration.

Is David S. Kabakoff’s NextCure (NXTC) Form 4 transaction a market buy or sell?

No, the Form 4 shows a grant of stock options as compensation, not a market transaction. The code “A” indicates an award or other acquisition, so no cash was paid to buy shares and no shares were sold into the market.

How many NextCure (NXTC) derivative securities does David S. Kabakoff hold after this grant?

After the grant, Kabakoff holds stock options for 3,510 shares of NextCure common stock directly. This filing does not list additional derivative positions, so the 3,510-share option grant represents his reported derivative holding in this report.

What does the $2.02 exercise price mean for David S. Kabakoff’s NextCure (NXTC) options?

The $2.02 exercise price is the fixed cost per share Kabakoff would pay to convert his options into 3,510 common shares once vested. If he exercises, he pays $2.02 per share regardless of NextCure’s future market price at that time.